Extended Data Fig. 4: Distribution of genotype Pr in cancer immunotherapy cohorts. | Nature Cancer

Extended Data Fig. 4: Distribution of genotype Pr in cancer immunotherapy cohorts.

From: Negative trade-off between neoantigen repertoire breadth and the specificity of HLA-I molecules shapes antitumor immunity

Extended Data Fig. 4

The density of genotype Pr is shown for (a) all patients (n = 316), (b) melanoma patients treated with CTLA-4 inhibitors (n = 164), (c) non-small cell lung cancer (NSCLC) patients treated with PD-1 or PD-L1 inhibitors (n = 74) and (d) melanoma patients treated with PD-1 or PD-L1 inhibitors (n = 78). Dashed black vertical lines represent the 25th and 75th percentile values, while dashed red vertical lines represent the fixed genotype Pr cutoff of 2.076 used for patient classification.

Source data

Back to article page